- Poster presentation
- Open access
- Published:
Comparison of nifekalant and amiodarone for resuscitation after cardiopulmonary arrest due to shock-resistant ventricular fibrillation
Critical Care volume 15, Article number: P291 (2011)
Introduction
Nifekalant (NIF) is a pure potassium channel blocker developed in Japan and it has been used widely for treating fatal ventricular tachyarrhythmia since 1999. Because intravenous amiodarone (AMD) was approved in 2007 in Japan, there have been few studies about the comparison of the efficacy of NIF and AMD for resuscitation after cardiopulmonary arrest patients due to shock-resistant ventricular fibrillation.
Methods
We performed a retrospective study in 32 consecutive cardiopulmonary arrest patients treated by NIF or AMD due to more than twice shock-resistant ventricular fibrillation from April 2005 to October 2010. The statistical analyses performed by chi-square test and nonpaired t test.
Results
The mean (± SD) age was 62.2 ± 16.1 years and 25 of 32 were male patients. All 32 patients were treated with tracheal intubation and intravenous epinephrine. Seventeen patients received NIF administration and 15 patients received AMD. The average initial administration dose of NIF was 11.1 ± 3.4 mg and that of AMD was 171.7 ± 59.7 mg. The rate of return of spontaneous circulation (ROSC) was 41.2% (7/17) in the NIF administration group and 26.7% (4/15) in the AMD group. The survived discharge rate from our hospital was 29.4% (5/17) in the NIF group and 13.3% (2/15) in the AMD group. There were no significant differences between the two groups with the rate of ROSC and survived discharge. The mean interval from the antiarrhythmic drug (NIF or AMD) administration to ROSC was 7.8 ± 6.6 minutes (NIF) and 19.9 ± 11.7 minutes (AMD). There was significant difference between the interval of NIF and that of AMD (P < 0.05).
Conclusions
Although NIF is an anti-arrhythmic agent for life-threatening ventricular tachyarrhythmia, it does not have negative inotropic activity. NIF changes shock-resistant ventricular fibrillation to spontaneous circulation more quickly than AMD. NIF is strongly effective for resuscitation of shock-resistant ventricular fibrillation.
References
Nakaya H, et al.: Br J Pharmacol. 1993, 109: 157-163.
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Harayama, N., Nihei, S., Isa, Y. et al. Comparison of nifekalant and amiodarone for resuscitation after cardiopulmonary arrest due to shock-resistant ventricular fibrillation. Crit Care 15 (Suppl 1), P291 (2011). https://doi.org/10.1186/cc9711
Published:
DOI: https://doi.org/10.1186/cc9711